Bicara Therapeutics, Inc. (BCAX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$17.07-3.07%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Bicara Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.862
Annual ending 2026-12-31
Revenue	—	0
EPS	—	-3.422
Annual ending 2027-12-31
Revenue	—	0
EPS	—	-3.618

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Fund operations into first half of 2029	Bicara Therapeutics aims to fund operations into the first half of 2029.	Intact	Cash reserves fall below levels needed to fund operations into H1 2029	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Leadership commitment	A supporting condition in Bicara Therapeutics, Inc.'s published investment case. The stated target is No further significant insider share sales by CEO or key executives.	Under Pressure	Additional significant insider sales by CEO or key executives	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage operating losses	Management focuses on controlling operating losses, though losses grew from -$32.0M in 2025-Q2 to -$60.2M in 2026-Q1.	Under Pressure	Operating losses worsen beyond -$60.2M per quarter	Operating income: $-59.951M FY2026-Q2; GAAP. Published target: Operating losses do not worsen beyond -$60.2M per quarter. Target period is not explicitly aligned with this observation. Source published Aug 11, 2026-59,951,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: a203d3d6-f836-4c39-b4ac-2a8ef40b87d5. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-3.62

$-3.70 → $-3.62 · observed estimates

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-3.70	Unavailable	10 / 0
2026-07-25	$-3.70	Unavailable	10 / 0
2026-07-26	$-3.70	Unavailable	10 / 0
2026-07-27	$-3.70	Unavailable	10 / 0
2026-07-28	$-3.63	$0	12 / 12
2026-07-29	$-3.63	$0	12 / 12
2026-07-30	$-3.63	$0	12 / 12
2026-07-31	$-3.63	$0	12 / 12
2026-08-01	$-3.63	$0	12 / 12
2026-08-02	$-3.63	$0	12 / 12
2026-08-03	$-3.63	$0	12 / 12
2026-08-04	$-3.63	$0	12 / 12
2026-08-05	$-3.63	$0	12 / 12
2026-08-06	$-3.63	$0	12 / 12
2026-08-07	$-3.70	Unavailable	10 / 0
2026-08-08	$-3.63	$0	12 / 12
2026-08-09	$-3.63	$0	12 / 12
2026-08-10	$-3.63	$0	12 / 12
2026-08-11	$-3.63	$0	12 / 12
2026-08-12	$-3.61	$0	12 / 11
2026-08-13	$-3.61	$0	12 / 11
2026-08-14	$-3.70	Unavailable	10 / 0
2026-08-15	$-3.70	Unavailable	10 / 0
2026-08-16	$-3.70	Unavailable	10 / 0
2026-08-17	$-3.70	Unavailable	10 / 0
2026-08-18	$-3.70	Unavailable	10 / 0
2026-08-19	$-3.70	Unavailable	10 / 0
2026-08-20	$-3.55	Unavailable	11 / 0
2026-08-21	$-3.55	Unavailable	11 / 0
2026-08-22	$-3.52	Unavailable	11 / 0
2026-08-23	$-3.52	Unavailable	11 / 0
2026-08-24	$-3.52	Unavailable	11 / 0
2026-08-25	$-3.52	Unavailable	11 / 0
2026-08-26	$-3.52	Unavailable	11 / 0
2026-08-27	$-3.52	Unavailable	11 / 0
2026-08-28	$-3.52	Unavailable	11 / 0
2026-08-29	$-3.52	Unavailable	11 / 0
2026-08-30	$-3.52	Unavailable	11 / 0
2026-08-31	$-3.52	Unavailable	11 / 0
2026-09-01	$-3.52	Unavailable	11 / 0
2026-09-02	$-3.52	Unavailable	11 / 0
2026-09-03	$-3.52	Unavailable	11 / 0
2026-09-04	$-3.52	Unavailable	11 / 0
2026-09-05	$-3.52	Unavailable	11 / 0
2026-09-06	$-3.52	Unavailable	11 / 0
2026-09-07	$-3.52	Unavailable	10 / 0
2026-09-08	$-3.52	Unavailable	10 / 0
2026-09-09	$-3.56	Unavailable	10 / 0
2026-09-10	$-3.56	Unavailable	10 / 0
2026-09-11	$-3.56	Unavailable	10 / 0
2026-09-12	$-3.56	Unavailable	10 / 0
2026-09-13	$-3.56	Unavailable	10 / 0
2026-09-14	$-3.56	Unavailable	10 / 0
2026-09-15	$-3.56	Unavailable	10 / 0
2026-09-16	$-3.56	Unavailable	10 / 0
2026-09-17	$-3.56	Unavailable	10 / 0
2026-09-18	$-3.56	Unavailable	10 / 0
2026-09-19	$-3.56	Unavailable	10 / 0
2026-09-20	$-3.56	Unavailable	10 / 0
2026-09-21	$-3.56	Unavailable	10 / 0
2026-09-22	$-3.56	Unavailable	10 / 0
2026-09-23	$-3.56	Unavailable	10 / 0
2026-09-24	$-3.56	Unavailable	10 / 0
2026-09-25	$-3.56	Unavailable	10 / 0
2026-09-26	$-3.56	Unavailable	10 / 0
2026-09-27	$-3.56	Unavailable	10 / 0
2026-09-28	$-3.56	Unavailable	10 / 0
2026-09-29	$-3.56	Unavailable	10 / 0
2026-09-30	$-3.56	Unavailable	10 / 0
2026-10-01	$-3.56	Unavailable	9 / 0
2026-10-02	$-3.62	Unavailable	9 / 0
2026-10-03	$-3.62	Unavailable	9 / 0
2026-10-04	$-3.62	Unavailable	9 / 0
2026-10-05	$-3.62	Unavailable	9 / 0
2026-10-06	$-3.62	Unavailable	9 / 0
2026-10-07	$-3.62	Unavailable	9 / 0
2026-10-08	$-3.62	Unavailable	9 / 0
2026-10-09	$-3.62	Unavailable	9 / 0
2026-10-10	$-3.62	Unavailable	9 / 0
2026-10-11	$-3.62	Unavailable	9 / 0
2026-10-12	$-3.62	Unavailable	9 / 0
2026-10-13	$-3.62	Unavailable	9 / 0
2026-10-14	$-3.62	Unavailable	9 / 0
2026-10-15	$-3.62	Unavailable	9 / 0
2026-10-16	$-3.62	Unavailable	9 / 0
2026-10-17	$-3.62	Unavailable	9 / 0
2026-10-18	$-3.62	Unavailable	9 / 0
2026-10-19	$-3.62	Unavailable	9 / 0
2026-10-20	$-3.62	Unavailable	9 / 0
2026-10-21	$-3.62	Unavailable	9 / 0
2026-10-22	$-3.62	Unavailable	9 / 0
2026-10-23	$-3.62	Unavailable	9 / 0
2026-10-24	$-3.62	Unavailable	9 / 0

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	12	3
2026-06-01	12	3
2026-07-01	12	3
2026-08-01	13	3
2026-09-01	13	3
2026-10-01	13	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 13 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Morgan StanleyOct 20 · prior Aug 11

$39.00 → $41.00+5.1%

$0$22.55$45.10

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Fund operations into first half of 2029Direct metric needs a verified mapping
Leadership commitmentPublished status: Under Pressure
Manage operating lossesPublished status: Under Pressure

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-46.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Bicara Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology business, not a proven earnings compounder. Its long-term thesis is in a watch state: management is advancing key studies, but recent financial performance is weak and confidence in the evidence is low.

What's priced into Bicara Therapeutics, Inc.

The snapshot provides no valuation level or specific market expectations, so whether BCAX is cheap, fair, or expensive versus peers cannot be assessed. It reports low valuation fragility, but that does not establish what clinical or earnings progress the market already assumes.

What the fundamentals likely do

Near term, earnings risk is elevated after a recent miss and a run of misses; another guidance cut would add concern. Over the multi-year view, trial progress is tangible: the pivotal FORTIFI-HN01 study is on track for substantial enrollment by year-end 2026, and a randomized dosing study began in Q3 2026. Higher research spending reflects that work, while clinical-response evidence and commercial prospects remain uncertain.

What Bicara Therapeutics, Inc. hinges on

The thesis depends on continued trial execution and whether follow-up data support deep, durable responses with ficerafusp alfa. Near-term setbacks could come from lower guidance or worsening employment data, while stronger results and guidance from major healthcare companies could support the sector backdrop. The snapshot gives limited evidence on the recent material agreement, so its effect on the thesis is unclear.